Warning letter
Anderson Compounding Pharmacy, Inc. DBA Anderson Compounding Pharmacy: warning letter of Jan 13, 2020
FDA warning letter 598303 · Office of Pharmaceutical Quality Operations, Division II
Key facts
| Reference number | 598303 |
|---|---|
| Company | Anderson Compounding Pharmacy, Inc. DBA Anderson Compounding Pharmacy |
| Subject | Compounding Pharmacy/Adulterated Drug Products |
| Issue date | Jan 13, 2020 |
| Posted date | May 26, 2020 |
| Issuing office | Office of Pharmaceutical Quality Operations, Division II |
| Product type | Drugs |
| Inspection city | Bristol |
| Inspection ZIP | 37620 |
| Inspection start date | Mar 26, 2019 |
| Letter on fda.gov | fda.gov |
At a glance
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: